APTX News and Press, Aptinyx Inc. From 01/05/21

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virt...

Aptinyx (APTX) has recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy.Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the U.S.“This study in painful DPN repres...

Study has resumed following suspension of enrollment due to escalation of COVID-19 pandemic Aptinyx now has two parallel-design, placebo-controlled Phase 2b studies ongoing with NYX-2925 in highly prevalent chronic pain indications Data readouts for NYX-2925 studies in...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference. Norbert...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company’s current chief operating officer, to the role of preside...

SCWorx (WORX) +100%.Professional Diversity Network (IPDN) +25%.Apex Technology Acquisition (APXT) +20%.Genfit SA (GNFT) +18%.Xinyuan Real Estate (XIN) +17% on Q3 results.Rhythm Pharmaceuticals (RYTM) +16% as FDA OKs it's Imcivree for weight management in obese patients.Shi...

From Monday's high, the S&P 500 is down nearly 4%. There are some concerns that the vaccine may result in a stimulus bill not passing. This would be bad for the economy in the short-term as case counts are rising. Investors need to be even more judicious when making their stock picks. If ...

Aptinyx Inc (APTX) Q3 2020 Results Conference Call November 12, 2020 05:00 PM ET Company Participants Nick Smith - Senior Director, Corporate Development & IR Norbert Riedel - President & Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Andy...

Aptinyx (APTX): Q3 GAAP EPS of -$0.24 beats by $0.06.Revenue of $0.26M (-72.3% Y/Y) misses by $0.15M.Press Release For further details see: Aptinyx EPS beats by $0.06, misses on revenue

Significant development progress across clinical-stage pipeline programs, with multiple clinical and regulatory milestones expected over the next 18 months Recommenced patient recruitment in Phase 2b clinical study of NYX-2925 in patients with fibromyalgia Near-term re...